CLINICAL TRIAL: STATIN TRIAL

临床试验：他汀类药物试验

• 批准号: 7724991
• 负责人: RUTH MULNARD MCCARGAR
• 金额: $ 0.05万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-12-01 至 2008-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7724991
• 关键词: Activities of Daily Living; Alzheimer' s Disease; Animal Model; Behavioral Symptoms; Cell Culture System; Cholesterol; Class; Clinical; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Data; Economics; Epidemiologic Studies; Funding; Grant; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Institution; Laboratories; Laboratory Research; Lipids; Measures; Observational Study; Pathology; Placebos; Quality of life; Recruitment Activity; Research; Research Personnel; Resources; Simvastatin; Source; United States National Institutes of Health; base; cohort; hypercholesterolemia

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. There is compelling evidence from laboratory research in animal model and cell culture systems, observational epidemiological studies, and small clinical trials that lowering cholesterol may reduce the pathology of Alzheimer's disease (AD). This is a clinical trial of simvastatin, a HMG CoA reductase inhibitor, the most commonly used class of lipid lowering agents, to reduce the clinical progression of Alzheimer's disease. The following evidence supports this hypothesis and is the basis for this study. Based on data accrued from observational studies, and that derived in the laboratory, we hypothesize that simvastatin will significantly reduce the clinical progression of AD as measured by the ADAScog. We also hypothesize that those who use simvastatin will show beneficial effects over placebo on measures of activities of daily living, psychiatric and behavioral symptoms, quality of life and economic measures. To study these hypotheses, we propose to recruit a cohort of 400 subjects with AD who do not have hypercholesterolemia.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 从实验室研究中，动物模型和细胞培养系统，观察性流行病学研究以及小型临床试验的令人信服的证据表明，降低胆固醇可能会减少阿尔茨海默氏病（AD）的病理学。 这是辛伐他汀（HMG COA还原酶抑制剂（最常用的脂质降低剂），可降低阿尔茨海默氏病的临床进展，这是HMG COA还原酶抑制剂的临床试验。 以下证据支持这一假设，是本研究的基础。 基于观察性研究的数据，并在实验室中得出的数据，我们假设辛伐他汀将大大降低ADASCOG测量的AD的临床进展。 我们还假设那些使用辛伐他汀的人将对安慰剂表现出对日常生活，精神病和行为症状，生活质量和经济措施的活动的有益影响。 为了研究这些假设，我们建议招募一个没有高胆固醇血症的AD的400名受试者。